Savara to Present at Two Upcoming Healthcare Conferences
January 31 2024 - 7:05AM
Business Wire
Guggenheim 6th Annual Biotechnology
Conference
Oppenheimer 34th Annual Healthcare Life
Sciences Conference
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical
company focused on rare respiratory diseases, today announced that
its management team will be participating at the following investor
healthcare conferences:
Guggenheim 6th Annual Biotechnology Conference February
7, 2024 at 8:30am PT/ 11:30am ET Fireside Chat St. Regis Hotel, New
York City, NY
Oppenheimer 34th Annual Healthcare Life Sciences
Conference February 13, 2024 at 7:40am PT / 10:40am ET
Corporate Presentation Virtual Conference
A webcast of each presentation will be available through the
Investors page of Savara’s website at
www.savarapharma.com/investors/events-presentations/ and will be
archived for at least 30 days.
About Savara
Savara is a clinical stage biopharmaceutical company focused on
rare respiratory diseases. Our lead program, molgramostim nebulizer
solution, is an inhaled granulocyte-macrophage colony-stimulating
factor (GM-CSF) in Phase 3 development for autoimmune pulmonary
alveolar proteinosis (aPAP). Molgramostim is delivered via an
investigational eFlow® Nebulizer System (PARI Pharma GmbH). Our
management team has significant experience in rare respiratory
diseases and pulmonary medicine, identifying unmet needs, and
effectively advancing product candidates to approval and
commercialization. More information can be found at
www.savarapharma.com. (X, formerly known as Twitter: @SavaraPharma,
LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240131762786/en/
Savara Inc. IR & PR Anne Erickson
anne.erickson@savarapharma.com (512) 851-1366
Savara (NASDAQ:SVRA)
Historical Stock Chart
From Apr 2024 to May 2024
Savara (NASDAQ:SVRA)
Historical Stock Chart
From May 2023 to May 2024